Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil.

@article{Weycker2007CosteffectivenessOM,
  title={Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil.},
  author={Derek Weycker and Charu Taneja and John S Edelsberg and Moshe Haim Erder and Frederick A. Schmitt and Juliana Setyawan and Gerry Oster},
  journal={Current medical research and opinion},
  year={2007},
  volume={23 5},
  pages={1187-97}
}
OBJECTIVE The efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease (AD) receiving stable doses of donepezil were recently demonstrated in a phase III trial. The cost-effectiveness of such therapy is unknown. RESEARCH DESIGN AND METHODS A microsimulation model was developed to depict AD progression over time and associated clinical and economic outcomes. AD progression was measured in terms of decline in cognitive function, as assessed by the Severe… CONTINUE READING

From This Paper

Topics from this paper.
20 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Similar Papers

Loading similar papers…